Edgewise Therapeutics vs LivaNova
Edgewise Therapeutics (EWTX), health care, and LivaNova (LIVN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
LivaNova is worth $5.1B on the stock market and Edgewise Therapeutics $4.6B: LivaNova is valued at 10% more. Edgewise Therapeutics trades at 5.2 times earnings and LivaNova at 26.5. Over the past year Edgewise Therapeutics's share price has moved +97.1% and LivaNova's +71.5%.
Key facts
- Edgewise Therapeutics market value
- $4.6B
- LivaNova market value
- $5.1B
- Edgewise Therapeutics P/E
- 5.2
- LivaNova P/E
- 26.5
- LivaNova revenue
- $1.4BFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Edgewise Therapeutics | LivaNova |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $4.6Blower | $5.1Bhigher |
| Revenue | — | $1.4B |
| Earnings | -$167.8Mhigher | -$242.5Mlower |
| Employees | 133lower | 3,300higher |
| Total assets | $552.6Mlower | $2.6Bhigher |
| Valuation | ||
| P/E | 5.2lower | 26.5higher |
| P/S | — | 3.6 |
| P/B | 2.8 | — |
| Dividend yield | 0.00% | — |
| Profitability | ||
| Operating margin | — | 14.4% |
| Balance sheet | ||
| Net assets | $522.3Mlower | $1.2Bhigher |
| Total liabilities | $30.3Mlower | $1.4Bhigher |
| Total debt | — | $376.7M |
| Cash on hand | $61.1Mlower | $635.6Mhigher |
| Price change | ||
| Today | -3.75%lower | -0.56%higher |
| 1 year | +97.1%higher | +71.5%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Edgewise Therapeutics only (2)
LivaNova only (1)
- Primecap team0.2%
Percentages are each holding's share of that investor's reported portfolio. Who owns EWTX · Who owns LIVN
More on Edgewise Therapeutics
Further comparisons
Edgewise Therapeutics against its closest peers
LivaNova against its closest peers
Learn
Questions and answers
Which is bigger, Edgewise Therapeutics or LivaNova?
By market value, LivaNova is the larger: $5.1B against $4.6B for Edgewise Therapeutics.
Which has the higher P/E ratio?
LivaNova: 26.5, against 5.2 for Edgewise Therapeutics. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which superinvestors own both Edgewise Therapeutics and LivaNova?
None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Edgewise Therapeutics and 1 holds LivaNova.
Cite this page
Funkfolio, “Edgewise Therapeutics vs LivaNova”, data as of 18 November 2026. https://funkfolio.com/compare/ewtx-vs-livn
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.